Co-Founder And Ceo
Current
Jun 2018 - Present
AeroLeads people directory · profile
Benjamin Fryer Email & Phone Number
Tomorrow's Cell Therapies, Today
at
Pluristyx, Inc.
1 work email found
@pluristyx.com
LinkedIn matched
✓ Verified May 2026
4 data sources
Profile completeness 100%
Current company
Role
Tomorrow's Cell Therapies, Today
Location
Seattle, Washington, United States
Who is Benjamin Fryer? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Benjamin Fryer is listed as Tomorrow's Cell Therapies, Today at Pluristyx, Inc., based in Seattle, Washington, United States. AeroLeads shows a work email signal at pluristyx.com and a matched LinkedIn profile for Benjamin Fryer.
Benjamin Fryer previously worked as Co-Founder and CEO at Pluristyx, Inc. and Team Leader, CMC, Cardiomyocyte Cell Manufacturing at University Of Washington. Benjamin Fryer holds Phd, Pharmacology from University Of Pennsylvania.
Company email context
Email format at Pluristyx, Inc.
This section adds company-level context without repeating Benjamin Fryer's masked contact details.
*@pluristyx.com
68% confidence
AeroLeads found 1 current-domain work email signal for Benjamin Fryer. Compare company email patterns before reaching out.
Profile bio
About Benjamin Fryer
Benjamin Fryer, PhD has almost 25 years of experience as a leader and scientist developing biopharmaceutical products and cell therapies in a wide array of settings including large pharma, start-up companies, and academia. He earned his doctorate in pharmacology at the University of Pennsylvania and completed a post-doctoral fellowship at a UPenn Howard Hughes Laboratory studying oxygen sensing and signaling in cancer and stem cell development.Ben is currently the co-founder and CEO of Pluristyx Inc., a tools and services company catering to companies developing cell and gene-modified cell therapies. Pluristyx offers a suite of products and services including custom made and catalog pluripotent stem cells, contract research and development services, and consulting to support cell and tissue therapy development, manufacturing, and commercialization. Ben is an inventor on multiple issued patents and patent applications including a bioreactor based, stem cell suspension expansion and differentiation process and a product currently marketed by Thermo-Fisher™ as Nunclon-Vita.
Listed skills include Cell Culture, Cell Biology, Drug Discovery, Molecular Biology, and 19 others.
Current workplace
Benjamin Fryer's current company
Company context helps verify the profile and gives searchers a useful next step.
5 roles
Benjamin Fryer work experience
A career timeline built from the work history available for this profile.
Team Leader, Cmc, Cardiomyocyte Cell Manufacturing
Jan 2015 - Apr 2018
Research Scientist
- Developed novel cell culture surface for adherent culture of pluripotent stem cells in collaboration with Thermo-Fisher Scientific (patent pending on surface marketed as Nuclon Vita ™)
- Identified serum-free culture conditions for differentiation of pluripotent stem cells to pancreatic precursor cells
- Discovered compound family to induce insulin expression in pancreatic precursor cells
- Led and managed laboratory with 5 FTE to produce cell therapy in scalable system
- Filed 7 patent applications
Nov 2006 - Dec 2014
Post-Doctoral Fellow
- Awarded F32 postdoctoral fellowship from National Institutes of Health
- Investigated the role of hypoxia and Hif in placental development and placental (trophoblast) stem cell differentiation with trangenic mice, in vitro cell studies, and molecular biology
- Developed and bred transgenic mouse model to study the effect of loss or gain of Hypoxia Inducible Factor (Hif) on p53 mutant (cancer prone) mice
- Researched the effect of Hif on tumor progression, type, vascularization, latency, and metastases
Jan 2005 - Oct 2006
Phd Student
- Demonstrated that the serine/threonine kinase, Pak (p21 activated kinase), is regulated by cGMP dependent protein kinase (PKG)
- Showed Kaposi’s Sarcoma herpes virus g-protein coupled receptor activates Pak, which in turn activates NF-kappa B which drives Kaposi’s Sarcoma, suggesting Pak inhibition could delay or reduce tumor growth
- Established that the serine/threonine kinase Akt phosphorylates Pak1 on Serine 21
Sep 1998 - Dec 2004
2 education records
Benjamin Fryer education
Phd, Pharmacology
University Of Pennsylvania
B.A., History
Colorado College
FAQ
Frequently asked questions about Benjamin Fryer
Quick answers generated from the profile data available on this page.
What company does Benjamin Fryer work for?
Benjamin Fryer works for Pluristyx, Inc..
What is Benjamin Fryer's role at Pluristyx, Inc.?
Benjamin Fryer is listed as Tomorrow's Cell Therapies, Today at Pluristyx, Inc..
What is Benjamin Fryer's email address?
AeroLeads has found 1 work email signal at @pluristyx.com for Benjamin Fryer at Pluristyx, Inc..
Where is Benjamin Fryer based?
Benjamin Fryer is based in Seattle, Washington, United States while working with Pluristyx, Inc..
What companies has Benjamin Fryer worked for?
Benjamin Fryer has worked for Pluristyx, Inc., University Of Washington, Janssen, Pharmaceutical Companies Of Johnson And Johnson, University Of Pennsylvania, and University Of Pennsylvania School Of Medicine.
How can I contact Benjamin Fryer?
You can use AeroLeads to view verified contact signals for Benjamin Fryer at Pluristyx, Inc., including work email, phone, and LinkedIn data when available.
What schools did Benjamin Fryer attend?
Benjamin Fryer holds Phd, Pharmacology from University Of Pennsylvania.
What skills is Benjamin Fryer known for?
Benjamin Fryer is listed with skills including Cell Culture, Cell Biology, Drug Discovery, Molecular Biology, Biotechnology, Signal Transduction, Clinical Trials, and Stem Cells.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial